Programme Hyperlipidemia Academy 2015 .pdf

Nom original: Programme Hyperlipidemia Academy 2015.pdf

Ce document au format PDF 1.6 a été généré par Adobe InDesign CS5 (7.0.4) / Adobe PDF Library 9.9, et a été envoyé sur le 05/10/2015 à 09:26, depuis l'adresse IP 84.233.x.x. La présente page de téléchargement du fichier a été vue 794 fois.
Taille du document: 889 Ko (4 pages).
Confidentialité: fichier public

Aperçu du document

4–5 December 2015
Starling Geneva Hotel, Geneva, Switzerland


Dear Colleagues,
On behalf of the Scientific Steering Committee, we have the pleasure of inviting you to attend the third annual
Hyperlipidemia Academy, a highly respected forum in Europe for sharing expert knowledge, education and real-world
experience. This event will be held at the Starling Geneva Hotel, Geneva, Switzerland, on 4–5 December 2015.
This stimulating 2-day meeting will bring together over 350 physicians from across Europe. With an agenda developed
by a European panel of experts, this engaging event will give delegates an important opportunity to hear updates on the
latest data and opinions in the management of patients with hypercholesterolemia. Recently published material on the
inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) will be considered and discussed with respect to the
potential of newly licensed monoclonal antibodies to help address the needs of patients at high risk of a cardiovascular
event. Throughout the meeting, we will also break out into a number of interactive workshop groups to discuss and
review a series of topical case studies with leading authorities in the field.
The Hyperlipidemia Academy will provide a forum for you to meet a renowned faculty and to establish relationships
with fellow physicians from across Europe.
We look forward to welcoming you to Geneva for what promises to be a highly informative meeting.

Professor Erik Stroes
(The Netherlands)

Professor Alberico Catapano

Friday 4 December 2015

Saturday 5 December 2015

13.30–13.35 Welcome to the 3rd Hyperlipidemia Academy

Bart Molemans (Amgen), François Mach (Switzerland)



13.35–13.45 Steering Committee’s opening remarks

Erik Stroes (The Netherlands)

13.45–14.45 Key PCSK9 data and breaking news

Ulrich Laufs (Germany), Kausik Ray (UK),

Klaus Parhofer (Germany)

14.45–15.15 In LDL-cholesterol we trust

John Chapman (France)
15.15–15.55 Refreshments
15.55–16.45 Moderated case study workshops – session 1

Eight different case studies will be presented
Selected faculty

17.00–17.40 Debate: Lowering LDL-C below 50 mg/dL is

safe and effective – fact or fantasy?
Fact: Kausik Ray
Fantasy: John Betteridge (UK)
17.40–18.10 Diabetic dyslipidemia and CVD

Marja-Riitta Taskinen (Finland)
18.10–18.15 Close of Day 1

Alberico Catapano (Italy)

Transfer to dinner



Welcome to Day 2
Alberico Catapano

Beyond LDL-C
Børge Nordestgaard (Denmark),
Luis Masana (Spain)

Statins: the opportunities and challenges
Erik Stroes, Kausik Ray

Hot topics in 2015
John Chapman, Eric Bruckert (France),
Luis Masana, Marja-Riitta Taskinen

10.45–11.15 Refreshments
11.15–12.00 PCSK9 experience: case studies from

clinical trials to early real-world experience

Ulrich Laufs, Erik Stroes, François Mach
12.15–13.05 Moderated case study workshops – session 2

Eight different cases will be presented

Selected faculty
13.05–14.00 Lunch
14.00–14.40 Familial hypercholesterolemia:

the need for better management

Kausik Ray
14.40–15.30 Journal club

A review of three recent publications

Selected faculty
15.30–15.55 Using genetics to inform clinical practice

DeCODE speaker
15.55–16.00 Meeting summary and close

Erik Stroes, Alberico Catapano

Amgen (Europe) GmbH
Dammstrasse 23, CH-6300 Zug, Switzerland
© 2015 Amgen Inc. All rights reserved.

Aperçu du document Programme Hyperlipidemia Academy 2015.pdf - page 1/4
Aperçu du document Programme Hyperlipidemia Academy 2015.pdf - page 2/4
Aperçu du document Programme Hyperlipidemia Academy 2015.pdf - page 3/4
Aperçu du document Programme Hyperlipidemia Academy 2015.pdf - page 4/4

Télécharger le fichier (PDF)

Sur le même sujet..

Ce fichier a été mis en ligne par un utilisateur du site. Identifiant unique du document: 00358743.
⚠️  Signaler un contenu illicite
Pour plus d'informations sur notre politique de lutte contre la diffusion illicite de contenus protégés par droit d'auteur, consultez notre page dédiée.